MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41440-024-01843-z

Медицинская библиотека · Hypertension research : official journal of the Japanese Society of Hypertension · 2024

Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial.

Wei Fang-Fei, Pellicori Pierpaolo, Ferreira João Pedro, González Arantxa, Mariottoni Beatrice, An De-Wei, Verdonschot Job A J, Liu Chen, Ahmed Fozia Z, Petutschnigg Johannes, Rossignol Patrick, Heymans Stephane, Cuthbert Joe, Girerd Nicolas, Clark Andrew L, Li Yan, Nawrot Tim S, Díez Javier, Zannad Faiez, Cleland John G F, Staessen Jan A, HOMAGE Investigators

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

None of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25-50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9. Quality of life (QoL) was assessed by EQ5D questionnaire. Between-group differences (spironolactone minus control [Δs]) were analyzed by repeated measures ANOVA with adjustment for baseline and, if appropriate, additionally for sex, age and body mass index. Δs in the pre-exercise systolic/diastolic BP were -8.00 mm Hg (95% CI, -11.6 to -4.43)/-0.85 mm Hg (-2.96 to 1.26) at month 1 and -9.58 mm Hg (-14.0 to -5.19)/-3.84 mm Hg (-6.22 to -1.47) at month 9. Δs in the post-exercise systolic/diastolic BP were -8.08 mm Hg (-14.2 to -2.01)/-2.07 mm Hg (-5.79 to 1.65) and -13.3 mm Hg (-19.9 to -6.75)/-4.62 mm Hg (-8.07 to -1.17), respectively. For completed shuttles, Δs at months 1 and 9 were 2.15 (-0.10 to 4.40) and 2.49 (-0.79 to 5.67), respectively. Δs in QoL were not significant. The correlations between the exercise-induced BP increases and the number of completed shuttles were similar in both groups. In conclusion, in patients at increased risk of developing HF, spironolactone reduced the pre- and post-exercise BP, but did not improve exercise capacity or QoL.

Для цитирования: Wei Fang-Fei, Pellicori Pierpaolo, Ferreira João Pedro, González Arantxa, Mariottoni Beatrice, An De-Wei, Verdonschot Job A J, Liu Chen, Ahmed Fozia Z, Petutschnigg Johannes, Rossignol Patrick, Heymans Stephane, Cuthbert Joe, Girerd Nicolas, Clark Andrew L, Li Yan, Nawrot Tim S, Díez Javier, Zannad Faiez, Cleland John G F, Staessen Jan A, HOMAGE Investigators. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial.. Hypertension research : official journal of the Japanese Society of Hypertension. 2024. DOI: 10.1038/s41440-024-01843-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.